Glycogen synthase kinase-3: A potential immunotherapeutic target in tumor microenvironment

Biomed Pharmacother. 2024 Apr:173:116377. doi: 10.1016/j.biopha.2024.116377. Epub 2024 Mar 5.

Abstract

Glycogen synthase kinase-3(GSK-3) is a protein kinase that can phosphorylate over a hundred substrates and regulate cell differentiation, proliferation, and death. Researchers have acknowledged the pivotal role of abnormal activation of GSK-3 in the progression of various diseases over the past few decades. Recent studies have mostly concentrated on investigating the function of GSK-3 in the tumor microenvironment, specifically examining the interaction between TAM, NK cells, B cells, and T cells. Furthermore, GSK-3 exhibits a strong association with immunological checkpoints, such as programmed cell death protein 1. Novel GSK-3 inhibitors have potential in tumor immunotherapy, exerting beneficial effects on hematologic diseases and solid tumors. Nevertheless, there is a lack of reviews about the correlation between tumor-associated immune cells and GSK-3. This study intends to analyze the function and mechanism of GSK-3 comprehensively and systematically in the tumor microenvironment, with a special focus on its influence on various immune cells. The objective is to present novel perspectives for GSK-3 immunotherapy.

Keywords: GSK-3; Immunotherapy; NK cells; T cells; Tumor microenvironment.

Publication types

  • Review

MeSH terms

  • Glycogen Synthase Kinase 3 beta
  • Glycogen Synthase Kinase 3*
  • Humans
  • Immunotherapy
  • Neoplasms* / therapy
  • T-Lymphocytes
  • Tumor Microenvironment

Substances

  • Glycogen Synthase Kinase 3
  • Glycogen Synthase Kinase 3 beta